Effectiveness of clozapine in neuroleptic-resistant schizophrenia: Clinical response and plasma concentrations

Journal of Psychiatry and Neuroscience

Volumn 27, Issue 1, 2002, Pages 30-37

  Llorca, Pierre Michel ^a   Lancon, Christophe ^a   Disdier, Béatrice ^a   Farisse, Jean ^a   Sapin, Christophe ^a   Auquier, Pascal ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Antipsychotic agents; Clozapine; Dose response relationship, drug; Drug monitoring; Schizophrenia

Indexed keywords

CLOZAPINE; CLOZAPINE N OXIDE; NEUROLEPTIC AGENT; NORCLOZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSALIVATION; MALE; PARKINSONISM; PATIENT MONITORING; RECEIVER OPERATING CHARACTERISTIC; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SENSITIVITY AND SPECIFICITY; SMOKING; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOZAPINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; ROC CURVE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0036246398     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking
2. Effects of gender and age on plasma levels of clozapine and its metabolites analyzed by critical statistics
3. Will routine therapeutic drug monitoring have a place in clozapine therapy?
4. Antipsychotic efficacy in relation to plasma levels of clozapine
5. Clozapine treatment of schizophrenic patients: Plasma concentration and coagulation factor
6. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients
7. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia
8. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
9. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics
10. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges
11. Clozapine and negative symptoms. An open study
12. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
13. The positive and negative syndrome scale (PANSS) for schizophrenia
14. Validity and reliability of the french language version of the positive and negative syndrome scale (PANSS)
15. Positive and Negative Syndrome Scale
16. The extrapyramidal symptom rating scale
17. Concentrations plasmatiques de la clozapine et ses métabolites chez les patients schizophrènes résistants
18. Factorial structure of the Positive and Negative Symptom Scale (PANSS): A forced five-dimensional factor analysis
19. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine
20. Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
21. Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients
22. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: A cross-sectional study
23. Clozapine:pharmacokinetic investigations and biochemical effects in man
24. Clozapine-benzodiazepine interactions